Albouy M, Sanquer A, Maynard L, Eun H M
Research and Development Department, Virbac, bp 27, 06511 Carros Cedex, France.
Vet Rec. 2008 Aug 9;163(6):179-83. doi: 10.1136/vr.163.6.179.
A multicentre randomised clinical trial was performed to compare the therapeutic potential of osaterone acetate with that of delmadinone acetate in the treatment of benign prostatic hyperplasia in dogs. The osaterone was administered orally at 0.25 mg/kg bodyweight once a day for seven days to 73 dogs. The delmadinone was administered by a single intramuscular or subcutaneous injection at 3 mg/kg bodyweight to 69 dogs. During the 180-day trial, the dogs were monitored five times for their clinical signs and prostate volume. The two drugs were similarly effective in reducing the clinical signs and inducing complete clinical remission, and both induced a similar level of minor, mostly transitory adverse effects. Osaterone reduced the volume of the prostate glands of the dogs significantly more quickly than delmadinone.
进行了一项多中心随机临床试验，以比较醋酸奥沙睾酮与醋酸甲地孕酮治疗犬良性前列腺增生的治疗潜力。将醋酸奥沙睾酮以0.25mg/kg体重口服，每天一次，连续7天，给药73只犬。将醋酸甲地孕酮以3mg/kg体重单次肌肉注射或皮下注射，给药69只犬。在180天的试验期间，对犬的临床症状和前列腺体积进行了5次监测。两种药物在减轻临床症状和诱导完全临床缓解方面同样有效，且都引起了相似程度的轻微、大多为短暂的不良反应。醋酸奥沙睾酮比醋酸甲地孕酮能更快地显著缩小犬前列腺的体积。
